The safety profile of favipiravir in COVID-19 patients with severe renal impairment

Basit Öğe Kaydı
dc.authoridBahçecioğlu, Ömer Faruk/0000-0002-4045-4555
dc.authoridErsoy, Yasemin/0000-0001-5730-6682
dc.authoridDurmus, Mefkure/0000-0001-9745-4196
dc.authoridulutas, ozkan/0000-0002-2155-8340
dc.authoridGOK, Selim/0000-0003-3179-1899
dc.authoridAYTEMUR, ZEYNEP AYFER/0000-0003-0421-907X
dc.authorwosidBahçecioğlu, Ömer Faruk/AAA-7477-2021
dc.authorwosidErsoy, Yasemin/AAE-4811-2020
dc.authorwosidDurmus, Mefkure/ISR-9328-2023
dc.authorwosidulutas, ozkan/ABI-6332-2020
dc.contributor.authorGok, Selim
dc.contributor.authorBahcecioglu, Omer Faruk
dc.contributor.authorDurmus, Mefkure
dc.contributor.authorGun, Zeynep Ulku
dc.contributor.authorErsoy, Yasemin
dc.contributor.authorAytemur, Zeynep Ayfer
dc.contributor.authorUlutas, Ozkan
dc.date.accessioned2024-08-04T20:50:44Z
dc.date.available2024-08-04T20:50:44Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective The safety profile of favipiravir in patients with severe renal impairment has not been investigated and available data are insufficient. The study aimed to compare the incidence of favipiravir-associated adverse events amongst patients with varying renal function statuses. Methods Records of 921 patients who were hospitalised for COVID-19 and had received at least 5 days of favipiravir treatment were retrospectively evaluated and 228 patients were included in the study. Patients' age, sex, comorbidities, estimated glomerular filtration rate (eGFR) and haematological and biochemical values were recorded. The incidence of adverse events was compared with the age, sex, comorbidities and eGFR of the patients. Results The mean age of the patients was 59.3 +/- 15.6 years, and 38.2% of the patients were women. One hundred and thirty-one (57.5%) patients had experienced adverse events. These adverse effects consisted of ALT elevation (35.5%), AST elevation (21.5%), anaemia (16.2%), hyperuricaemia (10.5%), hepatocellular injury (9.2%), neutropenia (3.5%) and thrombocytopenia (2.6%). The incidence of adverse events was not significantly different when patients had eGFR >60 mL/min/1.73 m(2) or eGFR 30-60 mL/min/1.73 m(2) (P > .05), but significantly increased when the eGFR dropped to <30 (P < .05). The differences seen with hyperuricaemia and anaemia were significant (P < .05). Conclusion Even though favipiravir appeared to be well tolerated in the individuals with renal failure in this study, its use in this population remains a challenge that requires more research and analysis.en_US
dc.identifier.doi10.1111/ijcp.14938
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue12en_US
dc.identifier.pmid34605126en_US
dc.identifier.scopus2-s2.0-85116725986en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1111/ijcp.14938
dc.identifier.urihttps://hdl.handle.net/11616/100253
dc.identifier.volume75en_US
dc.identifier.wosWOS:000705112300001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Hindawien_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDefinitionen_US
dc.titleThe safety profile of favipiravir in COVID-19 patients with severe renal impairmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu